Clinical Trials Logo

Clinical Trial Summary

The University of North Carolina will test the effectiveness of the Centers for Disease Control and Prevention's AFIX model for increasing HPV vaccination coverage among adolescents. AFIX (Assessment, Feedback, Incentives and eXchange) consists of brief quality improvement consultations that immunization specialists from state health departments deliver to vaccine providers in primary care settings. Using immunization registry data, the specialist evaluates the clinic's vaccination coverage and delivers education on best practices to improve coverage. We will compare changes in HPV vaccination coverage before and after consultations for high-volume pediatric and family medicine clinics across three study conditions: traditional consultations (in-person group), virtual consultations (webinar group), or no consultations (control group). In each participating state, 30 clinics will be randomly assigned to each study arm, for a total of 90 clinics per state, or 270 clinics overall. The primary objective of this study is to compare the change in coverage for HPV vaccine initiation among 11-12 year old patients, from baseline to 6-month follow-up. Secondarily, we will compare the change in coverage for other vaccines and age groups.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02370459
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase N/A
Start date April 2015
Completion date November 2016

See also
  Status Clinical Trial Phase
Completed NCT00359619 - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine Phase 2
Completed NCT00250276 - Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Phase 3
Completed NCT01031069 - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase 4
Recruiting NCT05266898 - Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV Phase 4
Completed NCT03763565 - Effectiveness of HPV Vaccine in Thai Adult Women
Completed NCT00877877 - Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. Phase 3
Completed NCT00811798 - Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects. Phase 3
Recruiting NCT05884697 - Let's K-Talk - HPV Study for Ethnic Koreans N/A
Completed NCT00637195 - Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299) Phase 3
Completed NCT00798265 - A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults Phase 1
Completed NCT00423046 - Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Phase 3
Completed NCT00294047 - Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Phase 3
Recruiting NCT04469569 - Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors N/A
Not yet recruiting NCT04671823 - Changes in the Prevalence of Oncogenic HPV Types
Active, not recruiting NCT05148559 - Impact of Adolescent Vaccine Reminder Notices Sent Via Preferred Method of Communication on HPV Vaccination N/A
Recruiting NCT03350698 - Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Phase 4
Completed NCT00456807 - Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Phase 3
Completed NCT03501992 - Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination N/A